Washington, D.C. 20549





Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

October 29, 2019


Allakos Inc.

(Exact name of registrant as specified in its charter)













(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer
Identification No.)

975 Island Drive, Suite 201

Redwood City, California 94065

(Address of principal executive offices, including zip code)

(650) 597-5002

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, par value $0.001


The Nasdaq Global Select Market







Item 7.01   Regulation FD Disclosure

On October 29, 2019, Dr. Evan Dellon made a presentation at the American College of Gastroenterology 2019 Annual Scientific Meeting titled “Efficacy and Safety of AK002 in Adult Patients with Active Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis: Primary Results from a Randomized, Double-Blind Placebo- Controlled Phase 2 Trial (ENIGMA Study)” (the “Presentation”). A copy of the Presentation made is attached to this Current Report on Form 8-K as Exhibit 99.1. 

The information contained in this Current Report on Form 8-K, including the attached Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Form 8-K, including the Presentation, contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, the ability of AK002 to continue to demonstrate rapid and sustained benefit in patients with eosinophil gastrointestinal diseases, the timing of the Company’s long-term extension study and the efficacy and safety results from such study, the timing and outcome of its end of the phase 2 meeting and Allakos’ ability to conduct a phase 3 study in EG and/or EGE and a phase 2/3 study in EoE. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Allakos’ early stages of clinical drug development; Allakos’ ability to timely complete clinical trials for, and if approved, commercialize AK002, its lead compound; Allakos’ ability to obtain required regulatory approvals for its product candidates; uncertainties related to the enrollment of patients in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success of later-stage clinical trials, regardless of the outcomes of preclinical testing and early-stage trials; market acceptance of Allakos’ product candidates; uncertainties related to the projections of the size of patient populations suffering from the diseases Allakos is targeting; Allakos’ ability to advance additional product candidates beyond AK002; Allakos’ ability to obtain additional capital to finance its operations; and other important risk factors set forth in Allakos’ most recent Annual Report on Form 10-K filed with the SEC on March 14, 2019, Quarterly Report on Form 10-Q filed with the SEC on August 5, 2019 and future reports to be filed with the SEC. These documents contain and identify important factors that could cause the actual results for Allakos to differ materially from those contained in Allakos’ forward-looking statements. Any forward-looking statements contained in this Form 8-K, including the Presentation[s], speak only as of the date hereof, and Allakos specifically disclaims any obligation to update any forward-looking statement, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits











American College Gastroenterology 2019 Annual Scientific Meeting Presentation dated October 29, 2019.







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Allakos Inc.





Date: October 29, 2019



/s/ Robert Alexander




Robert Alexander




Chief Executive Officer




Slide 1

AK002 (Antolimab) in Adult Patients with Active Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis: Primary Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial (ENIGMA Study; NCT03496571) Evan S. Dellon1, Kathryn A. Peterson2, Joseph A. Murray3, Gary W. Falk4, Nirmala Gonsalves5, Mirna Chehade6, John Leung7, Robert M. Genta8, Marc E. Rothenberg9, Paneez Khoury10, Adam C. Bledsoe3, Camilla Shaw11, Henrik S. Rasmussen11, Bhupinder Singh11, Alan T. Chang11, Amol P. Kamboj11, Ikuo Hirano5 1University of North Carolina, Chapel Hill, NC; 2University of Utah, Salt Lake City, UT; 3Mayo Clinic Rochester, Rochester, MN; 4University of Pennsylvania, Philadelphia, PA; 5Northwestern University, Chicago, IL; 6Icahn School of Medicine at Mount Sinai, New York, NY; 7Tufts University, Boston, MA; 8Baylor College of Medicine, Houston, TX; 9Cincinnati Children’s Hospital, Cincinnati, OH; 10NIAID/NIH, Bethesda, MD; 11Allakos, Inc., Redwood City, CA. ACG 2019 San Antonio, TX October 25th-30th 2019 Exhibit 99.1

Slide 2

Eosinophilic Gastrointestinal Diseases (EGIDs) ESOPHAGUS STOMACH DUODENUM/ SMALL INTESTINE Eosinophilic Gastritis (EG) Eosinophilic Esophagitis (EoE) Eosinophilic Gastroenteritis (EGE) EG, EGE, EoE Chronic Eosinophilic Inflammation of the Stomach, Small Intestine, or Esophagus Symptoms: abdominal pain, nausea, early satiety, loss of appetite, bloating, abdominal cramping, vomiting, diarrhea, and dysphagia Eosinophils and mast cells are important drivers of disease Current standard of care: steroids; diet No FDA-approved treatment for EG, EGE, or EoE

Slide 3

AK002 Targets Siglec-8 on Eosinophils and Mast Cells Cell Membrane Activating Receptors Activation Siglec-8 Eosinophil Mast cell Inflammatory response AK002 Inhibition Eosinophil Mast cell ADCC/Apoptosis Inhibition AK002

Slide 4

ENIGMA Phase 2 Study Aim and Inclusion Study Aim Determine safety and efficacy of AK002 for treatment of EG and/or EGE Key Inclusion Criteria Active moderate to severe symptoms1 using the daily 8 symptom EG/EGE-SQ© Questionnaire Biopsy confirmed EG/EGE Stomach: ≥30 eos/hpf in 5 hpfs Duodenum: ≥30 eos/hpf in 3 hpfs 1PRO entry criteria: average weekly score over ≥2 weeks of ≥3 for either abdominal pain, diarrhea and/or nausea

Slide 5

ENIGMA Phase 2 Study Design AK002 Low (N=22) 0.3 → 1.0 → 1.0 → 1.0 mg/kg AK002 High (N=21) 0.3 → 1.0 → 3.0 → 3.0 mg/kg Placebo (N=22) Screening 2-4 Weeks Treatment 12 Weeks Follow-Up 8 Weeks EGD w/ Biopsy (Baseline) EGD w/ Biopsy (Day 99) Dose Day 1 Dose Day 29 Dose Day 57 Dose Day 85 EG/EGE

Slide 6

Endpoints Primary Endpoint Mean percent change in gastrointestinal eosinophil counts from baseline Symptoms Secondary Endpoint Mean percent change in Total Symptom Score (TSS) from baseline Responder Secondary Endpoint Proportion of patients who have: >75% decrease in tissue eosinophils AND >30% benefit in TSS Primary analysis with a pre-specified hierarchical per protocol approach Sensitivity analyses: ITT; subgroup with no steroid use

Slide 7

Baseline Characteristics AK002 Dose Groups Placebo (n=20) Total (N=59) High 0.3-3.0 mg/kg (n=20) Low 0.3-1.0 mg/kg (n=19) Combined High/Low (n=39) Age, Mean (Range) 42 (20-67) 43 (18-74) 42 (18-74) 40 (18-67) 41 (18-74) Female 60% 84% 72% 50% 64% White 85% 95% 90% 100% 93% Mean Gastrointestinal1 Eosinophils/hpf 76 80 78 75 77 Mean Gastrointestinal1 Mast Cells/hpf 59 70 64 56 62 Mean Total Symptom Score (TSS) [0-80] 34.1 34.7 34.4 30.1 32.9 % of Patients (n) by AEC2/µL <250 45% (9) 26% (5) 36% (14) 45% (9) 39% (23) 250 to <500 35% (7) 42% (8) 38% (15) 15% (3) 31% (18) 500 to <1500 20% (4) 21% (4) 21% (8) 35% (7) 25% (15) ≥1500 0% 11% (2) 5% (2) 5% (1) 5% (3) 1Gastric or duodenum site with highest eosinophil or mast cell counts 2AEC: Absolute Eosinophil Count

Slide 8

Primary Endpoint – Mean % Change in Eosinophil Count Treatment Arm Baseline Eosinophil Counts / hpf Mean %∆ in Eosinophil Counts p - value High Dose AK002 (n=20) 76 -97% <0.0001 Low Dose AK002 (n=19) 80 -92% <0.0001 Combined AK002 (n=39) 78 -95% <0.0001 Placebo (n=20) 75 +10% -

Slide 9

37 of 39 patients had < 6 eos/hpf; 31/39 had 0 eos/hpf Tissue Eosinophil Depletion % of Patients AK002 Placebo (0/20) (37/39) Stomach/Duodenal Eos < 6/hpf

Slide 10

Patient Reported Symptoms Secondary Endpoint Treatment Arm Baseline TSS Mean % Change in TSS p - value High Dose AK002 (n=20) 34 -58% 0.0012 Low Dose AK002 (n=19) 35 -49% 0.0150 Combined AK002 (n=39) 34 -53% 0.0012 Placebo (n=20) 30 -24% -

Slide 11

Rapid & Sustained Improvement in Symptoms Mean ± SEM % Change from BL Time (Weeks) EG/EGE-PRO Total Symptom Score 20 20 19 20 20 19 19 18 18 18 18 19 19 18 18 39 32 37 37 37 36 38 38 35 37 36 37 36 35 36 *p <0.05 Dose Placebo n= AK002 n= Placebo AK002 * * * * * * * * * * * * * *

Slide 12

Improvement Across All Symptoms EG/EGE-PRO Symptom Score AK002 (n=39) Median Score -59% -79% -100% -65% -61% -57% -47% -55% Baseline End of Tx

Slide 13

Improvements in TSS Were Not Driven by Any Single Symptom Mean Reduction in TSS Combined AK002 (N=39) Placebo (N=20) p - value Total Score -53.5% -24.3% 0.0012 Minus Abdominal Pain -53.1% -22.5% 0.0010 Minus Nausea -53.2% -23.9% 0.0009 Minus Vomiting -53.0% -24.9% 0.0018 Minus Satiety -51.8% -25.4% 0.0019 Minus Loss of Appetite -53.0% -24.9% 0.0009 Minus Abdominal Cramping -53.0% -22.4% 0.0011 Minus Bloating -55.9% -26.9% 0.0029 Minus Diarrhea -54.9% -24.0% 0.0010

Slide 14

AK002 Met Treatment Responder Secondary Endpoint Treatment Arm Treatment Responders p - value High Dose AK002 (n=20) 70% 0.0009 Low Dose AK002 (n=19) 68% 0.0019 Combined AK002 (n=39) 69% 0.0008 Placebo (n=20) 5% - Treatment responder defined as: >75% reduction in tissue eosinophil counts AND >30% reduction in symptoms (TSS)

Slide 15

Response in Concomitant EoE1 Severity of Dysphagia3 Esophageal Eos ≤ 6/hpf2 % of Patients AK002 Placebo *p <0.001† * (1/9) (13/14) Mean %∆ from BL AK002 (n=12) Placebo (n=8) 125 patients with concomitant EoE (≥15 eos/hpf or history of EoE) and baseline dysphagia 2Excludes patients with eos < 6/hpf at baseline. At end of treatment, 10/14 AK002 patients had 0 eos/hpf; 2/14 AK002 patients had 1 eos/hpf; 1/14 AK002 patients had 3 eos/hpf; 1/14 AK002 patients had 105 eos/hpf (biopsy occurred 6 weeks post last dose instead of 2 weeks per protocol); 1/9 placebo patients had 2 eos/hpf; 8/9 placebo patients had 19 – 200 eos/hpf 3All EoE patients with end of treatment dysphagia scores †p = 0.00015

Slide 16

Safety Summary Treatment-Emergent AEs in ≥5% of Patients % of Patients, (n) AK002 (n=43) Placebo (n=22) Infusion related reaction 60% (26) 23% (5) Headache 9% (4) 9% (2) Upper respiratory tract infection 9% (4) 9% (2) Urinary tract infection 9% (4) 5% (1) Nausea 7% (3) 14% (3) Fatigue 7% (3) 9% (2) Diarrhea 5% (2) 9% (2) Nasopharyngitis 5% (2) 9% (2) Abdominal pain 2% (1) 9% (2) Dehydration 2% (1) 9% (2) Gastroenteritis viral 2% (1) 9% (2) Pyrexia 2% (1) 9% (2) Sinusitis 2% (1) 9% (2) Cough 0% (0) 9% (2) Influenza 0% (0) 9% (2) White blood cell count increased 0% (0) 9% (2) Generally well tolerated Most common AE was mild to moderate infusion related reactions (IRR) 93% mild to moderate (flushing, feeling of warmth, headache, nausea, dizziness) Mostly on first infusion, greatly reduced or does not occur on subsequent infusions 1 drug-related serious adverse event, an IRR which recovered within 24 hours with no further sequelae Treatment-emergent SAEs: 9% on AK002, 14% on Placebo No other significant AEs

Slide 17

ENIGMA Summary This was the first randomized study in EG/EGE Study met all primary and secondary endpoints, demonstrating significant histologic and symptom improvements in EG/EGE Strong histologic and symptom improvements in EoE Generally well-tolerated These results build on clinical activity of AK002 observed in other atopic and mast cell disorders (chronic urticaria, severe allergic conjunctivitis, asthma, atopic dermatitis, and indolent systemic mastocytosis) Further development of AK002 for EG/EGE is appropriate

Slide 18

We thank the patients who participated in this study, investigators, and study staff